Ibrolipim
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL) -promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects[1][2][3].
Product Specifications
CAS Number
133208-93-2
Product Name Alternative
NO-1886
UNSPSC
12352005
Hazard Statement
H301
Target
Lipase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ibrolipim.html
Purity
99.48
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
BrC1=CC(C#N)=C(C=C1)NC(C2=CC=C(C=C2)CP(OCC)(OCC)=O)=O
Molecular Formula
C19H20BrN2O4P
Molecular Weight
451.25
Precautions
H301
References & Citations
[1]Chen SG, et al. Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 2010 Oct;31 (10) :1343-9.|[2]Kano S, et al. NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, accelerates the expression of UCP3 messenger RNA and ameliorates obesity in ovariectomized rats. Metabolism. 2006 Feb;55 (2) :151-8.|[3]Liu Y, et al. Preventive effect of Ibrolipim on suppressing lipid accumulation and increasing lipoprotein lipase in the kidneys of diet-induced diabetic minipigs. Lipids Health Dis. 2011 Jul 16;10:117.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
EKU08838 96 Tests
Human Transforming Growth Factor Beta 1 (TGFb1) CLIA Kit
Sign In for Pricing
View Details K1170904 1.0 µg DNA
KRT18P8 sgRNA CRISPR Lentivector (Human) (Target 3)
Sign In for Pricing
View Details 
K4253005 3x 1.0 µg
Olfr482 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
Sign In for Pricing
View Details 